Hematology and Oncology

Accelerating market approvals for life-saving compounds: our formula for your success

TFS HealthScience provides hematology and oncology scientific, medical, regulatory, and operational expertise and tailored solutions to ensure the successful execution of complex oncology trials. This highly specialized discipline requires extreme attention to detail combined with a broad understanding of your requirements. Your trial is unique—we have the strategy and experts to support it from design to completion.

By engaging TFS hematology and oncology CRO services, you gain access to:

  • Global, international, and regional experience in oncology

  • Partnership-minded approach and customer-centric focus

  • Access to our global key opinion leaders and site network

  • In-depth therapeutic, scientific, and strategic knowledge

  • Operational delivery excellence through proactive planning, risk mitigation, and standardized processes

  • Commitment and executive oversight from TFS’ most senior personnel, including our hemato-oncology leadership team

About one-third of TFS studies are in the oncology and hematology area

We built our expertise through longstanding hands-on experience covering a broad range of indications across all phases of development.

  • Early Phase

    Supporting your research and development strategically at its crucial go/no-go stage

  • Phases II - III

    Taking your drug or product to approval

  • Late Phase

    Getting the real-world data you need

  • Consulting

    Providing commercially and therapeutically relevant advice to support your decisions throughout clinical development

  • Resources

    Enhancing and integrating with your in-house or outsourced resources as and when needed

  • Colorectal
  • Hematologic Malignanci
  • Prostate
  • Breast
  • Lung
  • Kidney/Renal
  • Melanoma
  • Liver
  • Head and Neck
  • Bone
  • Advanced Solid Tumors
  • Ovarian
  • Other Cancers

Case Study: First-in-Man Solid Tumor Oncology

TFS was selected to provide full CRO services including site identification, initiation, and training; patient enrollment, monitoring, data management, biostatistics, and programming; project management; medical writing, safety, medical monitoring, and regulatory consulting. This open study required close follow up on safety and disease progression.

Part One: (Dose Escalation): 3 sites
Part Two: (Dose Expansion): 6 sites
Study Phase: First-in-Man, I/IIb
Indication: Solid Tumors
Sites: 6

Read about the challenges and TFS solution

Experience you can trust

The TFS hematology and oncology team has specialists who understand the challenges of modern hematology and oncology trials. From complex early phase trials, including basket trials, precision medicines, immuno-oncology, and rare hematologic diseases, we are here to support the development of your trial.

Our experience over the last five years includes indications such as NSCLC, breast cancer, prostate cancer, solid tumors, HPV/cervical cancer, and malignant hematology studies.

  • Nearly 800 sites vetted and managed
  • More than 300 studies performed
  • Nearly 9,000 patients participated

One project, one team

TFS is committed to developing a solution-driven partnership that drives your success. Located across more than 20 countries, our depth and range of expertise can be put to use for your next global, regional, or local trial.

  • Bin Pan, PhD

    Head of Hematology-Oncology
    Clinical Development Services

    • Provide strategic guidance and operational leadership to internal cross functional teams as well as a consultative approach in developing novel solutions for biotech organizations
    • Expertise in adoptive cellular therapies, targeted small molecules, immuno-oncology clinical development across solid tumors and hematological malignancies
    • More than 20 years’ experience in all phases of oncology clinical development programs for pharmaceutical and biotechnology clients
    • Scientific background in biochemistry and molecular biology, and postdoctoral research in cellular signaling pathways

Right people, right solutions

If you are looking for a responsive mid-size CRO who understands hemato-oncology development, you are in the right place. We are the right people with the right solutions and we have the expertise to support that claim. Work with us and let us demonstrate real collaboration—talk to us today.